Jacobi Hospital team receives funding for PE imaging study
AngioDynamics (ANGO) announced a $50,000-$750,000 research grant for Jacobi Hospital to study imaging biomarkers in pulmonary embolism patients, aiming to predict treatment success. The study is supported by The PERT Consortium and focuses on CT pulmonary angiography radiomics.
How this was made
The 30-second read
Why it matters
The announcement adds a new research partnership, signaling continued investment in innovation but with limited immediate financial impact.
Market read
A modest, newly disclosed research grant to AngioDynamics may generate slight positive sentiment but is unlikely to drive significant price movement.
What to watch
Potential future collaborations or licensing deals stemming from the research could amplify long‑term impact.
Background
AngioDynamics (NASDAQ:ANGO) is a medical‑technology firm focused on vascular treatments. The ALPHA‑PE Research Fund, in partnership with The PERT Consortium, supports independent studies on pulmonary embolism imaging.
Ticker impact
AngioDynamics announced a new ALPHA-PE Research Fund award to Jacobi Hospital for imaging biomarker studies, a fresh funding grant disclosed today.
likely slight upward pressure as investors view the research funding as a positive catalyst.
The award is a new, primary disclosure but the amount is relatively small, so any price move is expected to be limited.
Market effects
Highlights ongoing interest in pulmonary embolism imaging, modestly supporting the broader vascular‑device sector.
U.S. market impact limited to AngioDynamics; no broader regional effect.
Minimal global relevance beyond niche medical‑technology investors.
Counterpoint
The grant size is too small to materially affect valuation; investors may ignore it.
Key entities
- CompanyAngioDynamics Inc.
US‑listed medical‑technology company receiving the research grant.
- InstitutionJacobi Hospital
Bronx hospital selected to receive the research funding.
